Sfoglia per AUTORE
BAROSI G
Collezione ASL Alessandria

  

Items : 2

Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results. in Blood / Blood. 2017 Oct 12;130(15):1768-1771. doi: 10.1182/blood-2017-02-765032. Epub 2017 Aug 21.

2017
ASL Alessandria

Barosi G; Rambaldi A; Passamonti F; Verstovsek S; Assad A; Granier M; Zhen H; Pieri L; Gattoni E; Rumi E; Barbui T; Vannucchi AM; Cazzola M; Kantarjian HM;

A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea in Cancer

2014
ASL Alessandria

Gattoni E; Pieri L; Guglielmelli P; Elena C; He S; Contel N; Mookerjee B; Sandor V; Cazzola M; Kantarjian HM; Barbui T; Vannucchi AM; Verstovsek S; Passamonti F; Rambaldi A; Barosi G; Rosen PJ; Rumi E;